FDA Scientists Question Safety of Popular Peptides Amid Advocacy for Deregulation
The Food and Drug Administration (FDA) is urging caution regarding the use of certain peptides, despite advocacy from Secretary of Health Robert F. Kennedy Jr. for their deregulation. FDA scientists assert that there is insufficient evidence to support recommending these substances for clinical use.
Upcoming FDA Advisory Committee Meeting to Discuss Peptide Manufacturing
Next month, FDA scientists are set to present their findings to an advisory committee that will evaluate the potential authorization of compounding pharmacies to manufacture seven distinct peptides. This review follows increasing interest in these substances from various wellness advocates.
Understanding Peptides and Their Surge in Popularity
Peptides are short chains of amino acids, fundamental components of proteins, that are produced naturally in the body but can also be synthesized in labs. Recently, they have gained traction among wellness influencers and podcasters who promote them as solutions for a range of issues, including weight loss and injury recovery. Kennedy has stated that he experienced “really good results” from using peptides to treat injuries.
Concerns Over Unregulated Peptide Market
Most peptides are currently sold on the “gray market” and lack FDA approval, making them available through unregulated online suppliers. In April, Kennedy reclassified 12 peptides as Category 1 substances, paving the way for potential production by compounding pharmacies, which create customized drug formulations. He criticized the Biden administration for erroneously labeling these peptides as safety risks during a congressional hearing.
Limited Human Research Raises Red Flags
Experts are concerned that most peptides have only been studied in animal models, resulting in insufficient data regarding their safety and efficacy in humans. Many peptides are marketed as “for research use only,” allowing vendors to circumvent regulations. Some experts, including Kennedy, argue that facilitating access through licensed compounding pharmacies would help regulate these products and protect consumers.
Upcoming Evaluation of Seven Peptides by FDA Advisory Committee
The FDA’s Pharmacy Advisory Committee will convene on July 23 and 24 to weigh the evidence surrounding seven peptides: BPC-157, emideltide, epitalon, KPV, MOTS-c, semax, and TB-500. This committee, comprised of independent experts, will provide recommendations to the FDA, though the agency ultimately makes the final decision regarding approval.
Safety Risks and Previous Committee Decisions
Dr. Anita Gupta, an anesthesiologist and former committee member, noted previous votes against certain peptides due to safety concerns, including risks of immunogenicity. She highlighted apprehensions about contamination in products dispensed through pharmacies, citing studies that have revealed significant issues such as heavy metal presence and microbial contamination.
Insufficient Evidence for Proposed Peptide Uses
A recent briefing paper from FDA scientists indicated that many peptides under evaluation lacked adequate human study data. Notably, the committee found that other FDA-approved treatments already exist for conditions often attributed to these peptides, like insomnia and eczema. The findings also revealed limited research on popular peptides like BPC-157 and semax, raising questions about their efficacy and prompting concern over a perceived inconsistency in regulatory scrutiny compared to conventional vaccines.
